What is Moderna Price-to-Operating-Cash-Flow?
As of today (2024-04-26), Moderna's share price is $107.97.
Moderna's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.00. Hence, Moderna's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Moderna's Price-to-Operating-Cash-Flow or its related term are showing as below:
During the past 8 years, Moderna's highest Price-to-Operating-Cash-Flow Ratio was 97.90. The lowest was 4.08. And the median was 12.60.
Moderna's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $1.63.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.00.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Moderna was -168.20% per year.
Moderna Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Moderna's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moderna Price-to-Operating-Cash-Flow Chart
|
Moderna Annual Data
|
|
Trend |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
- |
19.64 |
8.04 |
15.00 |
- |
|
Moderna Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
15.00 |
64.07 |
- |
- |
- |
Competitive Comparison of Moderna's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Moderna's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moderna's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moderna's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Moderna's Price-to-Operating-Cash-Flow falls into.
Moderna Price-to-Operating-Cash-Flow Calculation
Moderna's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 107.97 | / | -7.998 |
| = | |
Moderna's Share Price of today is $107.97.
Moderna's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Moderna (Moderna) Business Description
Traded in Other Exchanges
Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Executives
| Stephen Hoge |
officer: President |
C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| James M Mock |
officer: Chief Financial Officer |
940 WINTER STREET, PERKINELMER, WALTHAM MA 02451 |
| Shannon Thyme Klinger |
officer: Chief Legal Officer |
200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139 |
| Noubar Afeyan |
director, 10 percent owner |
C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
| Arpa Garay |
officer: Chief Commercial Officer |
2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
| Stephane Bancel |
director, officer: Chief Executive Officer |
320 BENT STREET, CAMBRIDGE MA 02141 |
| Juan Andres |
officer: See Remarks |
C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Paul Burton |
officer: Chief Medical Officer |
200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| David W Meline |
officer: Chief Financial Officer |
3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000 |
| Jorge M Gomez |
officer: See Remarks |
C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277 |
| Paul Sagan |
director |
AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
| Tal Zvi Zaks |
officer: Chief Medical Officer |
C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX |
| Lori M. Henderson |
officer: General Counsel and Secretary |
MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778 |
| Le Goff Corinne |
officer: Chief Commercial Officer |
200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139 |
| Elizabeth G Nabel |
director |
BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115 |
Moderna (Moderna) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRNA has been successfully added to your